BMC Cancer

Table 3 Mean difference of fatigue scores

From: Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial

BFI						FACIT
		Number	mean ± standard division	SE	P-value	mean ± standard division	SE	P-value
Baseline	Placebo	14	5.4 ± 0.6	0.16	0.3	24.6 ± 7.5	2	0.6
Baseline	Bupropion	13	5.8 ± 1.2	0.3	0.3	23.15 ± 7.2	2	0.6
End of 2_nd week	Placebo	14	5.3 ± 0.5	0.14	0.8	25.2 ± 7	1.8	0.7
End of 2_nd week	Bupropion	13	5.2 ± 1.3	0.36	0.8	26.3 ± 7.3	2	0.7
End of 6_th week	Placebo	14	4.9 ± 0.7	0.19	0.006	26.5 ± 6.8	1.8	0.15
End of 6_th week	Bupropion	13	4 ± 0.9	0.25	0.006	30.2 ± 6.1	1.7	0.15

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com